Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 283 of 5804
-
New drug cocktail targets hard-to-treat stomach cancer before surgery
Disease control Recruiting nowIn this study, the investigators will use Tislelizumab combined with LM-302 and S-1 versus Tislelizumab combined with SOX to treat Claudin 18.2-positive locally advanced gastric or gastroesophageal junction adenocarcinoma.
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New PET scan could revolutionize staging of deadly cancers
Diagnosis Recruiting nowPancreatic cancer is one of the worst-prognosed cancers with a 5-year survival rate of less than 10%. Its incidence has been steadily increasing for several years in France and worldwide. Pancreatic adenocarcinoma may become the second leading cause of cancer mortality in the yea…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:26 UTC
-
Modified virus boosts immunotherapy in kidney cancer trial
Disease control Recruiting nowThis phase II trial tests adding VSV-IFNβ-NIS to standard of care ipilimumab and nivolumab for the treatment of clear cell renal cell carcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spre…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New shot could help kids with bleeding disorder avoid bruising
Disease control Not yet recruitingThe purpose of this study is to evaluate efficacy and of safety QL0911 in the treatment of thrombocytopenia in pediatric patients with previously treated chronic ITP.
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for tough esophageal cancer: phase 3 trial launches
Disease control Recruiting nowThis study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune che…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug aims to boost height in kids with dwarfism
Disease control Recruiting nowThis is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2/3 study of BMN 333 in treatment-naïve pediatric participants with achondroplasia (ACH). The study consists of a Phase 2 part and a Phase 3 part.
Phase: PHASE2, PHASE3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New cocktail of immunotherapy, targeted drug, chemo, and radiation takes on lung cancer
Disease control Not yet recruitingThis is a single-arm, single-center, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. The study evaluates the effectiveness and safety of first-line treatment with benmelstobart (an immunotherapy), anlotinib (an anti-angiogenic drug), platin…
Phase: PHASE2 • Sponsor: Yayi He • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New hope for advanced lung cancer: combo therapy targets tough tumors
Disease control Not yet recruitingThis is a single-center, single-arm, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. It aims to evaluate the efficacy and safety of first-line treatment with benmelstobart plus anlotinib and chemotherapy (carboplatin/cisplatin plus etoposid…
Phase: PHASE2 • Sponsor: Yayi He • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New triple combo aims to tackle Hard-to-Treat liver cancer
Disease control Not yet recruitingThis prospective, single-arm, multicenter Phase II clinical trial aims to evaluate the efficacy and safety of Benmelstobart plus anlotinib combined with SBRT in patients with oligometastatic hepatocellular carcinoma who have failed first-line targeted therapy. Key study questions…
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Immunotherapy plus chemotherapy shows promise in rectal cancer trial
Disease control Recruiting nowThis is a multicenter, phase III, randomized controlled trial. Eligible patients with pMMR/MSS locally advanced rectal cancer will be randomized in a 1:1 ratio to either the experimental group or the control group using stratified randomization, with mesorectal fascia (MRF) statu…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug duo aims to slash myeloma relapse after transplant
Disease control Not yet recruitingTo explore the efficacy and safety of thiotepa combined with melphalan for ASCT conditioning in patients with multiple myeloma who did not acheive CR with or without extramedullary inflitration before transplantation. After screening and enrollment, the patients were randomly di…
Phase: NA • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill vs. infusion: which works better for severe colitis?
Disease control Recruiting nowThis clinical trial aims to evaluate the comparative efficacy and safety of upadacitinib versus infliximab as second-line treatments for acute severe ulcerative colitis, addressing the following key questions: (1) Can upadacitinib as a second-line therapy effectively induce remis…
Phase: PHASE4 • Sponsor: Xijing Hospital of Digestive Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising new combo aims to shrink returning throat tumors
Disease control Not yet recruitingThis exploratory clinical study will enroll patients with unresectable locally recurrent nasopharyngeal carcinoma to receive two cycles of becotatug vedotin plus a PD-1 monoclonal antibody, followed by sequential radiotherapy and PD-1 monoclonal antibody maintenance until disease…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to stall advanced lung cancer
Disease control Not yet recruitingThis study intends to carry out prospective, randomized controlled clinical trials in many centers across the country to compare the efficacy and safety of immunotherapy after standard first-line chemotherapy or immunotherapy combined with interventional bronchial artery chemoemb…
Phase: PHASE4 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can existing COVID drug beat dengue? new trial begins
Disease control Recruiting nowThis is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection * Primary objectives: * To determine the antiviral effectiveness of the experimental drug(s) in early dengue infection …
Phase: PHASE2 • Sponsor: Oxford University Clinical Research Unit, Vietnam • Aim: Disease control
Last updated Jun 27, 2026 12:27 UTC
-
New drug cocktail shows promise for tough head and neck cancers
Disease control ENROLLING_BY_INVITATIONThis is a multicenter, single-arm, phase II clinical study evaluating the efficacy and safety of neoadjuvant finotonlimab (anti-PD-1), cetuximab (anti-EGFR), and docetaxel in patients with resectable recurrent head and neck squamous cell carcinoma (HNSCC) who have progressed afte…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Blood test may guide breast cancer therapy, reducing chemo need
Disease control Recruiting nowExploring the dynamics of ctDNA following neoadjuvant therapy with CDK4/6 inhibitors combined with endocrine treatment, and its potential to guide de-escalation of adjuvant chemotherapy
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
A gentle touch may soothe Preemies' pain during blood tests
Symptom relief Recruiting nowPremature infants frequently experience painful procedures during their admission to neonatal intensive care units; this can lead to acute adverse events, imbalances, and long-term neurodevelopmental implications. This randomized controlled trial evaluates the impact of Gentle Hu…
Phase: NA • Sponsor: Kubra Nur Kabakcı Sarıdağ • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Engineered immune cells target abdominal tumors in colorectal cancer trial
Disease control Recruiting nowTo find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could J147 help stroke patients recover better?
Disease control Not yet recruitingThe goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients. Researchers will compare the outcomes of those who receive J147 a…
Phase: PHASE2 • Sponsor: Abrexa Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC